Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi Sells 2,274 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $95.91, for a total value of $218,099.34. Following the sale, the chief operating officer now directly owns 69,383 shares in the company, valued at $6,654,523.53. This trade represents a 3.17 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Christina Rossi also recently made the following trade(s):

• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.10, for a total transaction of $216,257.40.

Blueprint Medicines Trading Up 1.4 %

Shares of Blueprint Medicines stock opened at $90.14 on Friday. Blueprint Medicines Co. has a twelve month low of $72.24 and a twelve month high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The business has a 50-day moving average price of $92.45 and a 200-day moving average price of $97.23. The firm has a market cap of $5.73 billion, a price-to-earnings ratio of -42.72 and a beta of 0.59.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.08. The business had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm’s revenue for the quarter was up 126.5% compared to the same quarter last year. During the same quarter last year, the business posted ($2.20) EPS. Equities research analysts anticipate that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Blueprint Medicines

Large investors have recently bought and sold shares of the business. Raymond James & Associates raised its holdings in Blueprint Medicines by 45.2% during the 2nd quarter. Raymond James & Associates now owns 13,550 shares of the biotechnology company’s stock valued at $1,460,000 after buying an additional 4,215 shares during the period. EFG Asset Management North America Corp. raised its stake in shares of Blueprint Medicines by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock valued at $3,008,000 after acquiring an additional 132 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Blueprint Medicines by 13.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 273,930 shares of the biotechnology company’s stock worth $29,524,000 after purchasing an additional 32,740 shares during the period. Legato Capital Management LLC bought a new stake in Blueprint Medicines during the 2nd quarter valued at $557,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Blueprint Medicines by 8.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,792 shares of the biotechnology company’s stock worth $1,487,000 after buying an additional 1,064 shares during the period.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BPMC. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. UBS Group began coverage on shares of Blueprint Medicines in a research report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price on the stock. Finally, JPMorgan Chase & Co. started coverage on Blueprint Medicines in a research note on Thursday, November 14th. They set an “overweight” rating and a $126.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $122.11.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.